Inhibition of Overactive Transforming Growth Factor–β Signaling by Prostacyclin Analogs in Pulmonary Arterial Hypertension
![Targeting the Prostacyclin Pathway: Beyond Pulmonary Arterial Hypertension: Trends in Pharmacological Sciences Targeting the Prostacyclin Pathway: Beyond Pulmonary Arterial Hypertension: Trends in Pharmacological Sciences](https://www.cell.com/cms/attachment/e3fa9cf6-3b26-434a-babb-cc37c0e49c59/gr1_lrg.jpg)
Targeting the Prostacyclin Pathway: Beyond Pulmonary Arterial Hypertension: Trends in Pharmacological Sciences
![Frontiers | Additional Use of Prostacyclin Analogs in Patients With Pulmonary Arterial Hypertension: A Meta-Analysis Frontiers | Additional Use of Prostacyclin Analogs in Patients With Pulmonary Arterial Hypertension: A Meta-Analysis](https://www.frontiersin.org/files/MyHome%20Article%20Library/817119/817119_Thumb_400.jpg)
Frontiers | Additional Use of Prostacyclin Analogs in Patients With Pulmonary Arterial Hypertension: A Meta-Analysis
![Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension | European Respiratory Society Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension | European Respiratory Society](https://err.ersjournals.com/content/errev/24/138/630/F1.large.jpg)
Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension | European Respiratory Society
![JCM | Free Full-Text | Prostacyclin Analogues Inhibit Platelet Reactivity, Extracellular Vesicle Release and Thrombus Formation in Patients with Pulmonary Arterial Hypertension JCM | Free Full-Text | Prostacyclin Analogues Inhibit Platelet Reactivity, Extracellular Vesicle Release and Thrombus Formation in Patients with Pulmonary Arterial Hypertension](https://www.mdpi.com/jcm/jcm-10-01024/article_deploy/html/images/jcm-10-01024-g001.png)
JCM | Free Full-Text | Prostacyclin Analogues Inhibit Platelet Reactivity, Extracellular Vesicle Release and Thrombus Formation in Patients with Pulmonary Arterial Hypertension
Pulmonary arterial hypertension sensitive to calcium channel blocker, but not advanced pulmonary hypertension treatment: a case
![Management of prostacyclin side effects in adult patients with pulmonary arterial hypertension - Martha Kingman, Christine Archer-Chicko, Mary Bartlett, Joy Beckmann, Robin Hohsfield, Sandra Lombardi, 2017 Management of prostacyclin side effects in adult patients with pulmonary arterial hypertension - Martha Kingman, Christine Archer-Chicko, Mary Bartlett, Joy Beckmann, Robin Hohsfield, Sandra Lombardi, 2017](https://journals.sagepub.com/cms/10.1177/2045893217719250/asset/images/large/10.1177_2045893217719250-fig1.jpeg)
Management of prostacyclin side effects in adult patients with pulmonary arterial hypertension - Martha Kingman, Christine Archer-Chicko, Mary Bartlett, Joy Beckmann, Robin Hohsfield, Sandra Lombardi, 2017
![A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension - ScienceDirect A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0954611109002479-gr3.jpg)
A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension - ScienceDirect
![A meta‑analysis of the safety and efficacy of bosentan therapy combined with prostacyclin analogues or phosphodiesterase type‑5 inhibitors for pulmonary arterial hypertension A meta‑analysis of the safety and efficacy of bosentan therapy combined with prostacyclin analogues or phosphodiesterase type‑5 inhibitors for pulmonary arterial hypertension](https://www.spandidos-publications.com/article_images/etm/18/6/etm-18-06-4740-g03.jpg)
A meta‑analysis of the safety and efficacy of bosentan therapy combined with prostacyclin analogues or phosphodiesterase type‑5 inhibitors for pulmonary arterial hypertension
![Orally active prostacyclin analogue beraprost sodium in patients with chronic kidney disease: a randomized, double-blind, placebo-controlled, phase II dose finding trial – topic of research paper in Clinical medicine. Download scholarly article Orally active prostacyclin analogue beraprost sodium in patients with chronic kidney disease: a randomized, double-blind, placebo-controlled, phase II dose finding trial – topic of research paper in Clinical medicine. Download scholarly article](https://cyberleninka.org/viewer_images/1349663/f/1.png)
Orally active prostacyclin analogue beraprost sodium in patients with chronic kidney disease: a randomized, double-blind, placebo-controlled, phase II dose finding trial – topic of research paper in Clinical medicine. Download scholarly article
![Prostacyclin therapies for the treatment of pulmonary arterial hypertension | European Respiratory Society Prostacyclin therapies for the treatment of pulmonary arterial hypertension | European Respiratory Society](https://erj.ersjournals.com/content/erj/31/4/891/F3.large.jpg)
Prostacyclin therapies for the treatment of pulmonary arterial hypertension | European Respiratory Society
![The prostacyclin analogue treprostinil in the treatment of pulmonary arterial hypertension - Lindegaard Pedersen - 2020 - Basic & Clinical Pharmacology & Toxicology - Wiley Online Library The prostacyclin analogue treprostinil in the treatment of pulmonary arterial hypertension - Lindegaard Pedersen - 2020 - Basic & Clinical Pharmacology & Toxicology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/5a05735c-2349-4308-8024-f76bcc933ed1/bcpt13305-fig-0001-m.jpg)
The prostacyclin analogue treprostinil in the treatment of pulmonary arterial hypertension - Lindegaard Pedersen - 2020 - Basic & Clinical Pharmacology & Toxicology - Wiley Online Library
![Frontiers | The Prostacyclin Analogue, Treprostinil, Used in the Treatment of Pulmonary Arterial Hypertension, is a Potent Antagonist of TREK-1 and TREK-2 Potassium Channels Frontiers | The Prostacyclin Analogue, Treprostinil, Used in the Treatment of Pulmonary Arterial Hypertension, is a Potent Antagonist of TREK-1 and TREK-2 Potassium Channels](https://www.frontiersin.org/files/Articles/705421/fphar-12-705421-HTML/image_m/fphar-12-705421-g005.jpg)
Frontiers | The Prostacyclin Analogue, Treprostinil, Used in the Treatment of Pulmonary Arterial Hypertension, is a Potent Antagonist of TREK-1 and TREK-2 Potassium Channels
![PDF] A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension. | Semantic Scholar PDF] A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/f18ab0c7bcf3a6acd4fc2d522208a2a39d1595f0/4-Table1-1.png)
PDF] A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension. | Semantic Scholar
![Treprostinil pulmonary arterial hypertension drug molecule. Synthetic analogue of prostacyclin (PGI2). Blue skeletal formula on white background Stock Photo - Alamy Treprostinil pulmonary arterial hypertension drug molecule. Synthetic analogue of prostacyclin (PGI2). Blue skeletal formula on white background Stock Photo - Alamy](https://c8.alamy.com/zooms/6/c2d0e91039f4421f865944fb9ec17c1b/2c9jhry.jpg)